01358 PW MEDTECH
- 1.010
- -0.020-1.94%
PW MEDTECH News
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
普華和順：年報2023
PW MEDTECH To Go Ex-Dividend On July 4th, 2024 With 0.0495 HKD Dividend Per Share
April 1st - $PW MEDTECH(01358.HK)$ is trading ex-dividend on July 4th, 2024. Shareholders of record on July 5th, 2024 will receive 0.0495 HKD dividend per share on July 26th, 2024. The ex-dividend
PricewaterhouseCoopers (01358) will pay a final dividend of HK4.95 cents per share on July 26
PricewaterhouseCoopers (01358) announced that it will pay a final dividend of HK4.95 cents per share on July 26, 2024...
PW MEDTECH: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
PricewaterhouseCoopers (01358.HK) plans to hold a board meeting on March 28 to consider and approve the annual results
Glonghui, March 18, 丨 PricewaterhouseCoopers (01358.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday). The agenda includes approving the publication of the comprehensive annual results announcement of the company and its subsidiaries for the year ended December 31, 2023, and considering the payment of a final dividend proposal (if any).
PW MEDTECH: DATE OF BOARD MEETING
Changes in Hong Kong stocks | PricewaterhouseCoopers (01358) surged more than 10% after earnings, and is expected to achieve annual net profit of about $192 million to $215 million, up 49% to 67% year-on-year
The Zhitong Finance App learned that PricewaterhouseCoopers (01358) surged more than 10% to a new high. As of press release, it had risen 10.84% to HK$0.92, with a turnover of HK$1.17 million. According to the news, Pratt & Wah Heshun announced that the Group is expected to obtain a net profit of approximately RMB 192 million to RMB 215 million for the year ended December 31, 2023, an increase of 49% to 67% compared to approximately RMB 129 million for the year ended December 31, 2022; and to obtain profit attributable to the company owners of approximately RMB approximately RMB 119 million for the year ended December 31, 2023.
PW Medtech Sees Up To 55% Profit Growth in 2023
PW Medtech Group (HKG:1358) expects an attributable profit of between 142 million yuan and 165 million yuan for 2023, marking a growth of 33% to 55% from 106 million yuan in 2022, a Wednesday filing o
PricewaterhouseCoopers (01358.HK) Yingxi: Net profit is expected to increase 33% to 55% in 2023
Gelonghui, March 13, 丨 PricewaterhouseCoopers (01358.HK) announced that the Group is expected to (i) record a net profit of between RMB 192 million and RMB 215 million for the year ended December 31, 2023, an increase of 49% to 67% compared to approximately RMB 129 million in 2022; and (ii) record profit attributable to the company's owners in 2023 of between RMB 142 million and RMB 165 million, an increase of 33% to 55% compared with approximately RMB 106 million in 2022. This increase is mainly due to the Group's blood purification business and infusion devices
PW MEDTECH: POSITIVE PROFIT ALERT
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Highlights of the morning brokerage meeting: Focus on opportunities to increase the localization rate of medical devices
At today's brokerage morning meeting, CICC believes that it is concerned about opportunities to increase the localization rate of medical devices; CITIC Construction Investment pointed out that the future of the cross-border e-commerce industry has great potential; and Guotai Junan said that it is concerned about undervalued consumption of blue-chip stocks.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
PW Medtech Renews Purchase Deal With Lepu Medical
PW Medtech Group (HKG:1358) renewed its agreement with Lepu Medical (SHE:300003) for the purchase of medical devices molds and components worth up to 10 million yuan (HK$11.3 million), according to a
PW Medtech to Sell 2.51% Stake in Sichuan Ruijian Medical Technology
PW Medtech Group (HKG:1358) arm Medcore Investment will sell a roughly 2.51% stake in Sichuan Ruijian Medical Technology to the Shenzhen Venture Capital Manufacturing Transformation and Upgrading New
PricewaterhouseCoopers (01358): Shenzhen Venture Capital's Manufacturing Transformation and Upgrading New Materials Fund plans to invest in Sichuan Ruijian Healthcare
PricewaterhouseCoopers (01358) issued an announcement. On December 22, 2023, investors in Shenzhen Venture Capital's manufacturing industry were transformed and upgraded...
Financial News Agency Venture Capital Connect: In November, domestic healthcare financing of 5.931 billion yuan increased 49% month-on-month, and innovative drugs led the popularity
① In November 2023, there were 109 financing incidents in the domestic healthcare sector (excluding IPOs, targeted increases, etc.), a year-on-year decrease of 31% and an increase of 76% over the previous year; ② The total amount of financing disclosed in the healthcare sector during the same period was about 5.931 billion yuan, a decrease of 6% over the previous year and an increase of 49% over the previous year.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Analysis
Price Target
No Data
